-
1
-
-
33845592936
-
Rituximab: Novel B-cell depletion therapy for the treatment of rheumatoid arthritis
-
DOI 10.1517/14656566.7.18.2559
-
Dass S, Vital EM, Emery P. Rituximab: Novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2006;7:2559-70. (Pubitemid 44932458)
-
(2006)
Expert Opinion on Pharmacotherapy
, vol.7
, Issue.18
, pp. 2559-2570
-
-
Dass, S.1
Vital, E.M.2
Emery, P.3
-
2
-
-
33746961890
-
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
-
DOI 10.1002/art.22025
-
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
-
(2006)
Arthritis and Rheumatism
, vol.54
, Issue.9
, pp. 2793-2806
-
-
Cohen, S.B.1
Emery, P.2
Greenwald, M.W.3
Dougados, M.4
Furie, R.A.5
Genovese, M.C.6
Keystone, E.C.7
Loveless, J.E.8
Burmester, G.-R.9
Cravets, M.W.10
Hessey, E.W.11
Shaw, T.12
Totoritis, M.C.13
-
3
-
-
58849088519
-
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies
-
Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 216-221
-
-
Keystone, E.1
Emery, P.2
Peterfy, C.G.3
Tak, P.P.4
Cohen, S.5
Genovese, M.C.6
-
4
-
-
77953715791
-
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
-
Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158-61.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1158-1161
-
-
Cohen, S.B.1
Keystone, E.2
Genovese, M.C.3
Emery, P.4
Peterfy, C.5
Tak, P.P.6
-
5
-
-
82755193559
-
Multiple courses of rituximab produce sustained efficacy in patients with rheumatoid arthritis with an inadequate response to one or more TNF inhibitors
-
abstract
-
Keystone EC, Fleischmann RM, Emery P, Dougados M, Williams S, Linnik MD, et al. Multiple courses of rituximab produce sustained efficacy in patients with rheumatoid arthritis with an inadequate response to one or more TNF inhibitors [abstract]. Arthritis Rheum 2010;62 Suppl:S133.
-
(2010)
Arthritis Rheum
, vol.62
, Issue.SUPPL.
-
-
Keystone, E.C.1
Fleischmann, R.M.2
Emery, P.3
Dougados, M.4
Williams, S.5
Linnik, M.D.6
-
6
-
-
84881479853
-
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with focus on adverse events of interest in RA patients
-
in press
-
van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann R, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with focus on adverse events of interest in RA patients. Ann Rheum Dis [in press].
-
Ann Rheum Dis
-
-
Van Vollenhoven, R.F.1
Emery, P.2
Bingham III, C.O.3
Keystone, E.C.4
Fleischmann, R.5
Furst, D.E.6
-
7
-
-
77950307115
-
Treating rheumatoid arthritis to target: Recommendations of an international task force
-
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 631-637
-
-
Smolen, J.S.1
Aletaha, D.2
Bijlsma, J.W.3
Breedveld, F.C.4
Boumpas, D.5
Burmester, G.6
-
8
-
-
77953696525
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
-
Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 964-975
-
-
Smolen, J.S.1
Landewé, R.2
Breedveld, F.C.3
Dougados, M.4
Emery, P.5
Gaujoux-Viala, C.6
-
9
-
-
50249123223
-
Level of radiographic damage and radiographic progression are determinants of physical function: A longitudinal analysis of the TEMPO trial
-
van der Heijde D, Landewe R, van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: A longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008;67:1267-70.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1267-1270
-
-
Van Der Heijde, D.1
Landewe, R.2
Van Vollenhoven, R.3
Fatenejad, S.4
Klareskog, L.5
-
10
-
-
0036166382
-
COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention
-
DOI 10.1002/art.10083
-
Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56. (Pubitemid 34136571)
-
(2002)
Arthritis and Rheumatism
, vol.46
, Issue.2
, pp. 347-356
-
-
Landewe, R.B.M.1
Boers, M.2
Verhoeven, A.C.3
Westhovens, R.4
Van De, L.M.A.F.J.5
Markusse, H.M.6
Van Denderen, J.C.7
Westedt, M.L.8
Peeters, A.J.9
Dijkmans, B.A.C.10
Jacobs, P.11
Boonen, A.12
Van Der, H.D.M.F.M.13
Van Der, L.S.14
-
11
-
-
37149038223
-
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
-
DOI 10.1002/art.23141
-
van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39. (Pubitemid 350262318)
-
(2007)
Arthritis and Rheumatism
, vol.56
, Issue.12
, pp. 3928-3939
-
-
Van Der, H.D.1
Klareskog, L.2
Landewe, R.3
Bruyn, G.A.W.4
Cantagrel, A.5
Durez, P.6
Herrero-Beaumont, G.7
Molad, Y.8
Codreanu, C.9
Valentini, G.10
Zahora, R.11
Pedersen, R.12
MacPeek, D.13
Wajdula, J.14
Fatenejad, S.15
-
12
-
-
78149278597
-
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER
-
van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46.
-
(2010)
J Rheumatol
, vol.37
, pp. 2237-2246
-
-
Van Der Heijde, D.1
Breedveld, F.C.2
Kavanaugh, A.3
Keystone, E.C.4
Landewe, R.5
Patra, K.6
-
13
-
-
33646483031
-
The efficacy and safety of RTX in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial
-
Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of RTX in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 1390-1400
-
-
Emery, P.1
Fleischmann, R.2
Filipowicz-Sosnowska, A.3
Schechtman, J.4
Szczepanski, L.5
Kavanaugh, A.6
-
14
-
-
0031657148
-
Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs
-
DOI 10.1002/1529-0131(199809)41:9<1583::AID-ART8>3.0.CO;2-H
-
Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90. (Pubitemid 28459916)
-
(1998)
Arthritis and Rheumatism
, vol.41
, Issue.9
, pp. 1583-1590
-
-
Genant, H.K.1
Jiang, Y.2
Peterfy, C.3
Lu, Y.4
Redei, J.5
Countryman, P.J.6
-
15
-
-
70350539709
-
Progressive multifocal leukoencephalopathy following RTX treatment in a patient with rheumatoid arthritis
-
Fleischmann RM. Progressive multifocal leukoencephalopathy following RTX treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009;60:3225-8.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 3225-3228
-
-
Fleischmann, R.M.1
-
16
-
-
34848816866
-
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
-
DOI 10.1136/ard.2006.062760
-
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44. (Pubitemid 47492478)
-
(2007)
Annals of the Rheumatic Diseases
, vol.66
, Issue.10
, pp. 1339-1344
-
-
Askling, J.1
Fored, C.M.2
Brandt, L.3
Baecklund, E.4
Bertilsson, L.5
Feltelius, N.6
Coster, L.7
Geborek, P.8
Jacobsson, L.T.9
Lindblad, S.10
Lysholm, J.11
Rantapaa-Dahlqvist, S.12
Saxne, T.13
Van Vollenhoven, R.F.14
Klareskog, L.15
-
17
-
-
79951712039
-
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
-
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
-
(2011)
Rheumatology
, vol.50
, pp. 124-131
-
-
Galloway, J.B.1
Hyrich, K.L.2
Mercer, L.K.3
Dixon, W.G.4
Fu, B.5
Ustianowski, A.P.6
-
18
-
-
80053566154
-
Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
-
Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1914-1920
-
-
Strangfeld, A.1
Eveslage, M.2
Schneider, M.3
Bergerhausen, H.J.4
Klopsch, T.5
Zink, A.6
-
19
-
-
34447319146
-
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
-
DOI 10.1093/rheumatology/kem091
-
Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007;46:1191-9. (Pubitemid 47053782)
-
(2007)
Rheumatology
, vol.46
, Issue.7
, pp. 1191-1199
-
-
Bombardieri, S.1
Ruiz, A.A.2
Fardellone, P.3
Geusens, P.4
McKenna, F.5
Unnebrink, K.6
Oezer, U.7
Kary, S.8
Kupper, H.9
Burmester, G.R.10
-
20
-
-
52149099504
-
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial
-
Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1516-1523
-
-
Emery, P.1
Keystone, E.2
Tony, H.P.3
Cantagrel, A.4
Van Vollenhoven, R.5
Sanchez, A.6
-
21
-
-
80053571696
-
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: Open-label extension of the ATTEST Study
-
Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: Open-label extension of the ATTEST Study. Ann Rheum Dis 2011;70:2003-7.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 2003-2007
-
-
Schiff, M.1
Keiserman, M.2
Codding, C.3
Songcharoen, S.4
Berman, A.5
Nayiager, S.6
-
22
-
-
79955806071
-
Updated consensus statement on the use of RTX in patients with rheumatoid arthritis
-
Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al. Updated consensus statement on the use of RTX in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 909-920
-
-
Buch, M.H.1
Smolen, J.S.2
Betteridge, N.3
Breedveld, F.C.4
Burmester, G.5
Dörner, T.6
-
23
-
-
82355169068
-
Retreatment with RTX based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysis
-
Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Muller-Ladner U, Gaylis NB, et al. Retreatment with RTX based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysis. Rheumatology 2011;50:2223-32.
-
(2011)
Rheumatology
, vol.50
, pp. 2223-2232
-
-
Emery, P.1
Mease, P.J.2
Rubbert-Roth, A.3
Curtis, J.R.4
Muller-Ladner, U.5
Gaylis, N.B.6
|